{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-26-007340","form_type":"8-K","ticker":"XBIO","cik":"0001534525","company_name":"Xenetic Biosciences, Inc.","filed_at":"2026-09-23T21:20:22+00:00","discovered_at":"2026-09-23T21:22:00.360922+00:00","generated_at":"2026-09-23T21:22:08.269846+00:00","sec_items":["7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"medium","headline":"Xenetic-Santersus share exchange values combined company at $141M; XBIO holders ~15%","bullets":["Deal values Xenetic at ~$21M (15% pro forma) and Santersus at ~$120M (85%); 2,546,699 XBIO shares outstanding.","Expected to close Q4 2026; combined company to trade on Nasdaq under ticker SNTS.","NucleoCapture holds two FDA Breakthrough Device Designations; 80+ compassionate-use cases showed positive outcomes with no adverse events.","Lead sepsis program (~$5.6B market) targets potential EU launch in Q2 2028; CAR T lymphoma efficacy data expected Q2 2027.","Santersus options assumed by Xenetic; $0 net cash assumed, subject to adjustment per Share Exchange Agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-26-007340","json":"https://secwatch.observer/filing/0001683168-26-007340.json","markdown":"https://secwatch.observer/filing/0001683168-26-007340.md","text":"https://secwatch.observer/filing/0001683168-26-007340.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534525/000168316826007340/0001683168-26-007340-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534525/000168316826007340/xenetic_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-23T21:22:08.269846+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}